Frequency of EGFR gene mutations in patients with NSCLC in
Czech Republic

a 2014

Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic

KULTAN, Juraj; Vitezslav KOLEK; Ondrej FIALA; Jindrich FÍNEK; Miloš PEŠEK et. al.

Basic information

Original name

Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic

Authors

KULTAN, Juraj (203 Czech Republic); Vitezslav KOLEK (203 Czech Republic); Ondrej FIALA (203 Czech Republic); Jindrich FÍNEK (203 Czech Republic); Miloš PEŠEK (203 Czech Republic); Monika ŠATÁNKOVÁ (203 Czech Republic); Jana SKŘIČKOVÁ (203 Czech Republic, guarantor, belonging to the institution); Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution) and Zuzana ZBOŽÍNKOVÁ (203 Czech Republic, belonging to the institution)

Edition

14th Central European Lung Cancer Conference, 2014

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30203 Respiratory systems

Country of publisher

Spain

Confidentiality degree

is not subject to a state or trade secret

RIV identification code

RIV/00216224:14110/14:00080066

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002

Keywords in English

Epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); gene; mutation

Abstract

In the original language

Background: Worldwide, lung cancer is the most common cause of cancer-related death, and was responsible for 1.56 million deaths annually, as of 2012. The situation in the Czech Republic is identical, lung cancer is the leading cause of mortality due to malignant tumours, with 5,572 cancer related deaths in 2010. The detection of epidermal growth factor receptor (EGFR) gene mutations can guide targeted therapies for non-small cell lung cancer (NSCLC), because most of these mutations are strongly associated with clinical response to EGFR tyrosine kinase inhibitors. The aim of this study was to verify the frequency of EGFR mutations in a large group of Caucasians patients with advanced stage non-squamous NSCLC. Methods: Analysed data were collected in the period from November 15, 2011 to June 30, 2013 in three pneumo-oncological centres. Totally, 486 patients diagnosed with adenocarcinoma (459 cases) or NSCLC-NOS (27 cases) were tested for EGFR mutations, consisting of 284 males and 202 females, with median age of 66.5 years. Results: EGFR mutations were detected in 74 patients (15.2%). Mutations were shown in 25 (8.8%) men vs. 49 (24.3%) women (P<0.001), in 12 (6.7%) smokers vs. 20 (11.2%) ex-smokers vs. 38 (37.3%) non-smokers (P<0.001), and in 32 (15.7%) patients under 65 years of age vs. 42 (14.9%) patients over 65 years of age (P=0.898). Conclusions: The authors showed that the overall frequency of EGFR mutations in patients with non-squamous NSCLC was 15.2%, most commonly in female patients and non-smokers. The study results are in concordance with recent studies in which the frequency of EGFR mutations varies between 8-23% in Caucasian population. This information can help us to estimate number of patients who will need EGFR tyrosine kinase inhibitors in the first line of treatment.

Cite

KULTAN, Juraj; Vitezslav KOLEK; Ondrej FIALA; Jindrich FÍNEK; Miloš PEŠEK; Monika ŠATÁNKOVÁ; Jana SKŘIČKOVÁ; Zbyněk BORTLÍČEK and Zuzana ZBOŽÍNKOVÁ. Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic. In 14th Central European Lung Cancer Conference. 2014. ISSN 2218-6751. Available from: https://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002.

@proceedings{1297857,
   author = {Kultan, Juraj and Kolek, Vitezslav and Fiala, Ondrej and Fínek, Jindrich and Pešek, Miloš and Šatánková, Monika and Skřičková, Jana and Bortlíček, Zbyněk and Zbožínková, Zuzana},
   booktitle = {14th Central European Lung Cancer Conference},
   doi = {http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002},
   keywords = {Epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); gene; mutation},
   language = {eng},
   title = {Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic},
   year = {2014}
}

TY  - CONF
ID  - 1297857
AU  - Kultan, Juraj - Kolek, Vitezslav - Fiala, Ondrej - Fínek, Jindrich - Pešek, Miloš - Šatánková, Monika - Skřičková, Jana - Bortlíček, Zbyněk - Zbožínková, Zuzana
PY  - 2014
TI  - Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
KW  - Epidermal growth factor receptor (EGFR)
KW  - non-small cell lung cancer (NSCLC)
KW  - gene
KW  - mutation
N2  - Background: Worldwide, lung cancer is the most common cause of cancer-related death, and was responsible for 1.56 million deaths annually, as of 2012. The situation in the Czech Republic is identical, lung cancer is the leading cause of mortality due to malignant tumours, with 5,572 cancer related deaths in 2010. The detection of epidermal growth factor receptor (EGFR) gene mutations can guide targeted therapies for non-small cell lung cancer (NSCLC), because most of these mutations are strongly associated with clinical response to EGFR tyrosine kinase inhibitors. The aim of this study was to verify the frequency of EGFR mutations in a large group of Caucasians patients with advanced stage non-squamous NSCLC. Methods: Analysed data were collected in the period from November 15, 2011 to June 30, 2013 in three pneumo-oncological centres. Totally, 486 patients diagnosed with adenocarcinoma (459 cases) or NSCLC-NOS (27 cases) were tested for EGFR mutations, consisting of 284 males and 202 females, with median age of 66.5 years. Results: EGFR mutations were detected in 74 patients (15.2%). Mutations were shown in 25 (8.8%) men vs. 49 (24.3%) women (P<0.001), in 12 (6.7%) smokers vs. 20 (11.2%) ex-smokers vs. 38 (37.3%) non-smokers (P<0.001), and in 32 (15.7%) patients under 65 years of age vs. 42 (14.9%) patients over 65 years of age (P=0.898). Conclusions: The authors showed that the overall frequency of EGFR mutations in patients with non-squamous NSCLC was 15.2%, most commonly in female patients and non-smokers. The study results are in concordance with recent studies in which the frequency of EGFR mutations varies between 8-23% in Caucasian population. This information can help us to estimate number of patients who will need EGFR tyrosine kinase inhibitors in the first line of treatment.
ER  -

KULTAN, Juraj; Vitezslav KOLEK; Ondrej FIALA; Jindrich FÍNEK; Miloš PEŠEK; Monika ŠATÁNKOVÁ; Jana SKŘIČKOVÁ; Zbyněk BORTLÍČEK and Zuzana ZBOŽÍNKOVÁ. Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic. In \textit{14th Central European Lung Cancer Conference}. 2014. ISSN~2218-6751. Available from: https://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002.

Přehled o publikaci